Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
For most types of cancer, coffee appears either to decrease risk of cancer, or to have no effect on cancer risk at all. Even in countries with very high intake of caffeine from coffee, such as Scandinavian countries, research does not support a link between coffee or caffeine and breast cancer risk.....
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epitheli....
First of all, breast cancer isn't a death sentence: overall, about 60% of women survive breast cancer, and go on to live long and healthy lives. The percentage can be as high as 99%, depending on the particular type and stage of breast cancer. Stage 1, 2, 3 is easily curable by surgery followed b....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
كُتب بواسطة:Dr. Nitika Sharma - BDS
تمت مراجعته من قبل:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.